Truist analyst Asthika Goonewardene raised the firm’s price target on Iovance Biotherapeutics to $17 from $16 and keeps a Buy rating on the shares. The company’s acquisition of Proleukin is viewed positively as it allows Iovance to secure the supply chain, while providing only incremental sales potential, the analyst tells investors in a research note. Truist is also "encouraged" by the company’s data for lifileucel in PD-1 naive mNSCLC as disclosed in Iovance’s update, though it adds that the durability of response still needs to be established.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IOVA:
- Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M
- Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
- Akero Therapeutics appoints Patrick Lamy as SVP, commercial strategyIovance Biotherapeutics
- Barclays views GSK acquisition interest as positive for oncology stocks
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations